Skip to content

Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00958815
Enrollment
14
Registered
2009-08-13
Start date
2009-03-31
Completion date
2010-03-31
Last updated
2012-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Cardiovascular Disease, HIV/AIDS, HIV Infections, Insulin Resistance

Keywords

vascular imaging, diabetes, rupture prone plaques, HIV, treatment experienced

Brief summary

People with diabetes are at increased risk for atherosclerosis and have high CVD morbidity and mortality rates. Tools for detecting and quantifying atherosclerotic pro/regression in people with diabetes and other CVD risk factors lack sensitivity and specificity for molecular level events that occur during the early stages of atherogenesis. Inflammatory macrophage infiltration in the vessel endothelium is an early, molecular level proatherogenic event. Activated macrophages consume glucose at a high rate. Novel in vivo radiotracer PET/CT techniques have been developed to detect, image and quantify molecular level events like macrophage inflammation and glucose utilization (18FDG) in human vessels. We propose to develop and test this novel technique in the Center for Clinical Imaging Research (CCIR) at WUMS. We propose that HIV-infected people with significant CVD risk profiles are a suitable, unique human model for testing these novel imaging techniques. HIV-infected people taking anti-HIV medications develop insulin resistance, T2DM, dyslipidemia, central adiposity, and hypertension. HIV replicates in macrophages and represents a chronic proinflammatory condition. Recent data indicate that HIV+ CVD risk have greater risk for atherosclerosis and MI than HIV-negative people. To test feasibility, we hypothesize that: a.18FDG-PET/CT imaging will detect more macrophage glucose uptake and inflammation in the carotid and aorta arteries of HIV-infected people with CVD risk than in HIV-negative controls; b. radiotracer PET/CT measures of proatherogenic processes will correlate with carotid intima media thickness; a standard measure of carotid atherosclerotic burden. We propose to obtain pilot data that shows feasibility for a novel analytical approach that will expand capabilities for researchers interested in studying the links between diabetes, inflammation, and CVD in humans.

Interventions

None listed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

for HIV+ group: * confirmed HIV+ status * 35-60 years old * stable ART for at least the past 4 mos * CD4 count \>200 cells/µL * HIV RNA \<40copies/mL * fasting glucose=100-126 mg/dL * 2hr-oGTT glucose=140-200mg/dL * fasting triglycerides \>150mg/dL * HDL-cholesterol \<40mg/dL (men), \<50mg/dL (women) * resting blood pressure\>130/85mmHg * waist circumference \>102cm(men), \>88cm(women) * BMI 25-35 kg/m2 For HIV-negative control group: * Confirmed HIV negative status * 35-60 years old * fasting glucose\<100mg/dL, * 2hr-oGTT glucose\<140mg/dL * fasting triglycerides\<150mg/dL * HDL-cholesterol \>40mg/dL (men), \>50mg/dL(women) * normal BP (\<130/85mmHg) * no central adiposity (waist circ.\<102cm(men), \<88cm(women) * BMI (25-35 kg/m2)

Exclusion criteria

for both groups: * history of heart disease, MI, stroke, transient ischemic attack, kidney or liver disease (active hepatitis B or C), dementia * statins, fibrates, TZDs, antihypertensives, low dose aspirin, or other prescribed/over-the-counter agents with anti-inflammatory properties * cocaine and methamphetamine users * serum creatinine \>1.5 mg/dL * pregnant women * cognitive impairment that limits ability to provide voluntary informed consent

Design outcomes

Primary

MeasureTime frame
Standard uptake values (SUV) for 18Fluoro-deoxyglucose in the carotid vessels and aorta of HIV-infected people with cardiovascular disease risk factors and compared to the same in HIV-seronegative people with no cardiovascular disease risk factors.Baseline

Secondary

MeasureTime frame
Carotid intima media thickness measures will be compared to carotid 18FDG SUV.Baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026